Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
inotuzumab ozogamicin + temsirolimus
- Development stage
- Unknown
- Lead developer
- Pfizer
- Modality
- Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
inotuzumab ozogamicin + temsirolimus is a combination therapy investigated for the treatment of relapsed or refractory CD22-positive B-cell non-Hodgkin lymphoma. The combination consists of inotuzumab ozogamicin, a CD22-directed antibody-drug conjugate (ADC), and temsirolimus, a small molecule inhibitor of the mammalian target of rapamycin (mTOR). Inotuzumab ozogamicin (Besponsa) targets CD22-expressing B-cells and delivers a potent cytotoxic payload, calicheamicin, which induces double-strand DNA breaks and subsequent apoptosis. Temsirolimus (Torisel) inhibits the mTOR kinase, a central regulator of cell growth, proliferation, and survival that is often dysregulated in lymphomas. By combining targeted cytotoxicity with pathway inhibition, the regimen aims to overcome resistance and improve efficacy in patients with aggressive B-cell malignancies.
- Brand names
- BesponsaTorisel
- Other names
- Inotuzumab Ozogamicin and Temsirolimus
02
Targets
mTOR (Mammalian target of rapamycin kinase)CD22 (Cluster of Differentiation 22)DNA
Beyond the preview
Go deeper on inotuzumab ozogamicin + temsirolimus.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on inotuzumab ozogamicin + temsirolimus.